Literature DB >> 9016371

Pneumocystis carinii.

S J Levine1.   

Abstract

Improved understanding of Pneumocystis carinii, in particular the widespread use of chemoprophylaxis, has resulted in a declining incidence of infection in patients infected with HIV since the late 1980s. Despite these advances, P. carinii pneumonia continues to represent an important cause of pulmonary disease in HIV-seropositive individuals who do not receive chemoprophylaxis or when breakthrough episodes occur. This article reviews the history, biology, clinical manifestations, prognostic markers, therapy, and chemoprophylaxis of P. carinii pneumonia in HIV-seropositive patients.

Entities:  

Mesh:

Year:  1996        PMID: 9016371     DOI: 10.1016/s0272-5231(05)70339-7

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  2 in total

1.  Development and evaluation of a molecular viability assay for Pneumocystis carinii.

Authors:  N Maher; S Vermund; M Lasbury; C Lee; M Bartlett; T R Unnasch
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

2.  Predictors of high flow nasal cannula failure in immunocompromised patients with acute respiratory failure due to non-HIV pneumocystis pneumonia.

Authors:  Won-Young Kim; Heungsup Sung; Sang-Bum Hong; Chae-Man Lim; Younsuck Koh; Jin Won Huh
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.